Figure 7: Intratracheal application of rhMG53 protects LPS-induced lung remodelling in mice.
From: Treatment of acute lung injury by targeting MG53-mediated cell membrane repair
Animals were first treated with LPS (i.t., 3 times per week, for 5 weeks) followed by MBP-MG53 or MBP–MBP in control group (i.t., 5 days/week for 5 weeks). Lungs were collected 5 weeks after initial LPS application for evaluation. (a) MBP-MG53 prevents emphysema in LPS-induced chronic lung remodeling. (b) Histology haematoxylin and eosin staining of parenchyma in LPS-induced emphysematous lung (scale bars, 100 μm). (c) Statistical results for EELV, lung elastance and Lm in LPS-induced emphysematous lung treated with different doses of rMG53 (mg kg−1, 0.1, 0.3, 1.0) and 1 mg per kg control protein, n=7–10, *P<0.05 compared with no LPS control group (open bar) and #P<0.05 compared with saline-treated, LPS-challenged group. n=7–10 (Mann–Whitney U-analysis).
